Literature DB >> 11520584

Pooling of samples for seroepidemiological surveillance of human T-cell lymphotropic virus types I and II.

S Andersson1, A Gessain, G P Taylor.   

Abstract

We evaluated a straight forward pooling strategy for antibody screening of HTLV-I/II, using panels of sera from various parts of the world including a total of 43 HTLV-I and 54 HTLV-II positive specimens. Four antibody screening assays were included in the evaluation: the HTLV-I/II GE 80/81 (Murex Diagnostics), the HTLV-I/HTLV-II Ab Capture ELISA (Ortho Diagnostics), the HTLV-I/II ELISA 3.0 (Genelabs Diagnostics) and the Serodia HTLV-I (Fujirebio). The Murex and Ortho assays represent a new generation of HTLV screening tests with a sandwich format incorporating both HTLV-I and HTLV-II synthetic and/or recombinant peptide antigens. The Genelabs assay is an indirect ELISA with recombinant HTLV-I and -II antigens and Serodia is a particle agglutination assay with HTLV-I whole viral lysate. Each HTLV-positive sample was included in pools of 1/1 up to 1/16, in two-fold steps made in normal HTLV-negative blood donor serum from one up to nine donors. For HTLV-I, with the exception of one false negative sample in dilution 1/16 with Genelabs ELISA, all assays were positive at all dilutions. The Murex assay had absorbance values at maximum levels for all samples at all dilutions. The other assays had gradually decreasing absorbance values although clearly above cut-off. For HTLV-II, the Murex assay correctly detected all samples to dilution 1/16 despite gradually decreasing signals. The Serodia assay had 100% sensitivity to dilution 1/4 while at 1/8 and 1/16 it decreased 82 and 80%, respectively. The Genelabs ELISA had gradually decreasing sensitivity for HTLV-II from 98 (1/1) to 33% (1/16) while the Ortho assay detected all specimens at all dilutions in a limited set of samples tested. Taken together, this evaluation has shown that pooling of samples may be an appropriate strategy for serosurveillance of HTLV. It is, however, crucial to limit the number of samples and to choose assays that allow the dilution caused by the pooling. Using the best performing assays in this evaluation for pools of e.g. five samples would leave a reasonable safety margin.

Entities:  

Mesh:

Year:  2001        PMID: 11520584     DOI: 10.1016/s0168-1702(01)00289-1

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  6 in total

1.  High endemicity of human T-cell lymphotropic virus type 1 among pregnant women in peru.

Authors:  Jorge O Alarcón; Heidi B Friedman; Silvia M Montano; Joseph R Zunt; King K Holmes; Gerald V Quinnan
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

2.  Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain.

Authors:  Ana Treviño; Antonio Aguilera; Estrella Caballero; Rafael Benito; Patricia Parra; Jose M Eiros; Araceli Hernandez; Enrique Calderón; Manuel Rodríguez; Alvaro Torres; Juan García; Jose Manuel Ramos; Lourdes Roc; Goitzane Marcaida; Carmen Rodríguez; Matilde Trigo; Cesar Gomez; Raul Ortíz de Lejarazu; Carmen de Mendoza; Vincent Soriano
Journal:  Virol J       Date:  2012-03-23       Impact factor: 4.099

3.  Pooling of sera for human T-cell lymphotropic virus (HTLV) screening in a time of increasing health care expenditure and limited resources.

Authors:  Rafael Xavier da Silva; Karoline Rodrigues Campos; Adele Caterino-de-Araujo
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-05-11       Impact factor: 1.846

4.  Specificity of HTLV screening tests and its impact on health care program costs: The perspective of antenatal screening in Brazil.

Authors:  Carolina Rosadas; Adele Caterino-de-Araujo; Graham Philip Taylor
Journal:  Rev Soc Bras Med Trop       Date:  2021-03-08       Impact factor: 1.581

5.  HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience.

Authors:  Maria Piron; Fernando Salvador; Estrella Caballero; Adrián Sánchez-Montalvá; Marta Bes; Natàlia Casamitjana; Lluís Puig; Israel Molina; Silvia Sauleda
Journal:  Viruses       Date:  2022-09-06       Impact factor: 5.818

6.  Evaluation of Elecsys HTLV-I/II assay in comparison with ARCHITECT rHTLV-I/II assay with Korean samples.

Authors:  Seung Gyu Yun; Sang-Wook Kim; Ji Yeon Sohn; Yunjung Cho
Journal:  J Clin Lab Anal       Date:  2019-05-06       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.